SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

BioLargo Reports Third Quarter 2026 Results, Forecasting Commercial Breakout in 2027

Launches consumer products under its company-owned "barebird" brand featuring its CupriDyne technology; New distributors of Clyra Medical's ViaCLYR, pending 2027 new product line; BioLargo Engineering team grew revenue by 23% while also supporting PFAS and Cellinity projects; AEC PFAS treatment val…

BLGO

Related stories